These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 24586709)

  • 41. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.
    Bresson D; Fousteri G; Manenkova Y; Croft M; von Herrath M
    J Autoimmun; 2011 Dec; 37(4):342-51. PubMed ID: 22063316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.
    Piconese S; Valzasina B; Colombo MP
    J Exp Med; 2008 Apr; 205(4):825-39. PubMed ID: 18362171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.
    Fujiwara S; Nagai H; Shimoura N; Oniki S; Yoshimoto T; Nishigori C
    J Invest Dermatol; 2014 Jul; 134(7):1884-1892. PubMed ID: 24468748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
    Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
    PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.
    Voo KS; Bover L; Harline ML; Vien LT; Facchinetti V; Arima K; Kwak LW; Liu YJ
    J Immunol; 2013 Oct; 191(7):3641-50. PubMed ID: 24014877
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of anti-programmed cell death protein 1 monoclonal antibody combined with bevacizumab and/or Pseudomonas aeruginosa injection in transplanted tumor of mouse forestomach carcinoma cell gastric cancer in mice and its mechanism in regulating tumor immune microenvironment.
    Liu X; Yan C; Yang A; Yu E; Yu J; Zhou C; Wang Y; Wang K; Sun Y; Cheng Y
    Clin Exp Immunol; 2023 Oct; 213(3):328-338. PubMed ID: 37392409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
    Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
    Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
    Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
    J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
    Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
    Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
    [TBL] [Abstract][Full Text] [Related]  

  • 55. OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer.
    Lao J; Cao C; Niu X; Deng S; Ming S; Liang S; Shang Y; Yuan Y; Shi X; Liang Z; Wu M; Wu Y
    Int Immunopharmacol; 2022 Jul; 108():108813. PubMed ID: 35580452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma.
    McKee SJ; Doff BL; Soon MS; Mattarollo SR
    Cancer Immunol Res; 2017 Mar; 5(3):191-197. PubMed ID: 28115358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation.
    Wang HC; Klein JR
    J Immunol; 2001 Dec; 167(12):6717-23. PubMed ID: 11739485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.
    Nagato T; Lee YR; Harabuchi Y; Celis E
    Clin Cancer Res; 2014 Mar; 20(5):1223-34. PubMed ID: 24389326
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth.
    Badeaux MD; Rolig AS; Agnello G; Enzler D; Kasiewicz MJ; Priddy L; Wiggins JF; Muir A; Sullivan MR; Van Cleef J; Daige C; Vander Heiden MG; Rajamanickam V; Wooldridge JE; Redmond WL; Rowlinson SW
    Cancer Immunol Res; 2021 Apr; 9(4):415-429. PubMed ID: 33500272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.